Tyra biosciences receives ind clearance from fda to proceed with phase 2 study of tyra-300 in non-muscle invasive bladder cancer (surf302)

-tyra appoints urologic oncologist, erik goluboff, m.d., as svp, clinical development to lead nmibc- -first patient expected to be dosed in surf302 in q2 2025- carlsbad, calif.

TYRA Ratings Summary

TYRA Quant Ranking